MSMiles Shen

Miles Shen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Miles Shen has a total of 50 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Targeted Transcatheter Mitral Edge-to-Edge Repair for Dynamic Systolic Anterior Motion After Mitral Valve Repair

    by Ibrahim Naoum, Juliana Perez Pinzon, Miles Shen, Melissa Todice, Marc Pelletier, Emmanuel Akintoye, Amit N. Vora

  • Open Access

    Transcatheter Edge-to-Edge Repair of Mitral Valve Leaflet Perforation Guided by 3D Multiplanar Reconstruction Imaging

    by Miles Shen, Agastya Belur, Amit N. Vora, John K. Forrest, Emmanuel Akintoye

  • Evaluating the Accessibility of Transcatheter and Surgical Aortic Valve Replacement Across the US Via Driving-Times

    by Sohum Kapadia, Miles Shen, Jonathan Hanna, Kevin Wheelock, Aline F. Pedroso, Amit Vora, Lovedeep S. Dhingra, Arya Aminorroaya, Rohan Khera


  • Open Access

    Myocarditis‐Associated Cardiogenic Shock: A Nationwide Multicenter Study

    by Talal El Zarif, Alexander P. Ambrosini, Andi Shahu, Miles Shen, Maria G. Gastanadui, Israel Safiriyu, Avirup Guha, Mark Jacobs, Tariq Ali, Jennifer M. Kwan, et al.

    Background: There are limited data on the management of myocarditis‐associated cardiogenic shock. The aim of this study was to assess the clinical outcomes of patients with myocarditis‐associated cardiogenic shock. Methods: In this retrospective study using the Vizient Clinical Data Base, patients aged ≥18 years admitted with cardiogenic shock during 2015 through 2023 across the United States were stratified by myocarditis status. We assessed in‐hospital death by augmented inverse probability weighting, accounting for demographics, comorbidities, critical care therapies, and hospital characteristics. Results: A total of 621 695 patients with cardiogenic shock were included. Patients with myocarditis (n=2925; 0.5%) were younger (49.9 versus 65.2 years), more likely to be women (45.9% versus 36.7%), and had a lower Charlson comorbidity index (3.6 versus 4.4) but higher rates of cancer (13.5% versus 7.5%) and rheumatic disease (8.3% versus 3.4%) (all P P P =0.001). Conclusions: Myocarditis‐associated cardiogenic shock is uncommon yet represents a critically ill population with a higher adjusted in‐hospital mortality rate. Future work investigating therapies for this unique patient population is warranted.


  • Open Access

    Adverse cardiovascular events and cardiac imaging findings in patients on immune checkpoint inhibitors

    by Jennifer M Kwan, Miles Shen, Narjes Akhlaghi, Jiun-Ruey Hu, Ruben Mora, James L Cross, Matthew Jiang, Michael Mankbadi, Peter Wang, Saif Zaman, et al.

    Background: There is an urgent need to better understand the diverse presentations, risk factors, and outcomes of immune checkpoint inhibitor (ICI)-associated cardiovascular toxicity. There remains a lack of consensus surrounding cardiovascular screening, risk stratification, and clinical decision-making in patients receiving ICIs. Methods: We conducted a single center retrospective cohort study including 2165 cancer patients treated with ICIs between 2013 and 2020. The primary outcome was adverse cardiovascular events (ACE): a composite of myocardial infarction, coronary artery disease, stroke, peripheral vascular disease, arrhythmias, heart failure, valvular disease, pericardial disease, and myocarditis. Secondary outcomes included all-cause mortality and the individual components of ACE. We additionally conducted an imaging substudy examining imaging characteristics from echocardiography (echo) and cardiac magnetic resonance (CMR) imaging. Results: In our cohort, 44% (n = 962/2165) of patients experienced ACE. In a multivariable analysis, dual ICI therapy (hazard ratio [HR] 1.23, confidence interval [CI] 1.04–1.45), age (HR 1.01, CI 1.00–1.01), male sex (HR 1.18, CI 1.02–1.36), prior arrhythmia (HR 1.22, CI 1.03–1.43), lung cancer (HR 1.17, CI 1.01–1.37), and central nervous system (CNS) malignancy (HR 1.23, CI 1.02–1.47), were independently associated with increased ACE. ACE was independently associated with a 2.7-fold increased risk of mortality (PP = 0.045), with myo/pericarditis being associated with a 2.9-fold increased risk of mortality (P<0.001). However, the cardiovascular risks of dual ICI therapy were offset by its mortality benefit, with dual ICI therapy being associated with a ~25% or 1.3-fold decrease in mortality. Of those with echo prior to ICI initiation, 26% (n = 115/442) had abnormal left ventricular ejection fraction or global longitudinal strain, and of those with echo after ICI initiation, 28% (n = 207/740) had abnormalities. Of those who had CMR imaging prior to ICI initiation, 43% (n = 9/21) already had left ventricular dysfunction, 50% (n = 10/20) had right ventricular dysfunction, 32% (n = 6/19) had left ventricular late gadolinium enhancement, and 9% (n = 1/11) had abnormal T2 imaging. Conclusion: Dual ICI therapy, prior arrhythmia, older age, lung and CNS malignancies were independently associated with an increased risk of ACE, and dual ICI therapy was also independently associated with an increased risk of myo/pericarditis, highlighting the utmost importance of cardiovascular risk factor optimization in this particularly high-risk population. Fortunately, the occurrence of myo/pericarditis was relatively uncommon, and the overall cardiovascular risks of dual ICI therapy appeared to be offset by a significant mortality benefit. The use of multimodal cardiac imaging can be helpful in stratifying risk and guiding preventative cardiovascular management in patients receiving ICIs.


  • Open Access

    Contemporary National Patterns of Eligibility and Use of Novel Lipid‐Lowering Therapies in the United States

    by Miles Shen, Arash Aghajani Nargesi, Khurram Nasir, Deepak L. Bhatt, Rohan Khera

    Background: The emergence of PCSK9i (proprotein convertase subtilisin kexin type 9 inhibitor) and icosapent ethyl (IPE) has expanded the role of lipid‐lowering therapies beyond statins. Despite recommendations by clinical practice guidelines, their national eligibility and use rates remain unclear. Methods and Results: In the National Health and Nutrition Examination Survey data from 2017 to 2020, we assessed eligibility and the use of statins, PCSK9i, and IPE among US adults according to American College of Cardiology/American Heart Association guideline recommendations. Eligibility for PCSK9i and IPE were determined in the following 2 scenarios: (1) assuming existing lipid‐lowering therapy as the maximum tolerated before assessing eligibility for novel therapies and (2) assessing eligibility after assuming initiation and maximal escalation of preexisting lipid‐lowering therapies and accounting for expected lipid improvements. Of 2729 sampled individuals, representing 149.3 million adults, 1376 had indications for statins, representing 65.8 million or 44.0% (95% CI, 40.9%–47.2%) of adults. Current statin use was 45% of those eligible and was low across demographic groups. A total of 9.7 and 11.6 million adults would benefit from PCSK9i and IPE, respectively, based on lipid profiles and existing therapies. Assuming maximal escalation of statins and addition of ezetimibe, 4.1% (95% CI, 2.8%–5.4%) of adults or 6.1 million would benefit from PCSK9i and 6.8% (95% CI, 5.4%–8.3%) or 10.2 million from IPE. Conclusions: Six and 10 million individuals have clinical profiles whereby PCSK9i and IPE, respectively, would be expected to improve cardiovascular outcomes even after maximum escalation of statins and ezetimibe use, but remain undertreated with lipid‐lowering therapies. Optimal use of lipid‐targeted agents that include these novel agents is needed to improve population health outcomes.


  • Open Access

    Multisystem inflammatory syndrome in adults (MIS-A) associated with SARS-CoV-2 infection with delayed-onset myocarditis: case report

    by Miles Shen, Aidan Milner, Carlo Foppiano Palacios, Tariq Ahmad

    Background: During the Coronavirus disease 2019 (COVID-19) pandemic, reports have emerged of a multisystem inflammatory syndrome in adults (MIS-A). Multisystem inflammatory syndrome in adults can affect various organ systems, including cardiovascular, gastrointestinal, and neurologic systems without significant respiratory involvement. Case summary: A previously healthy 43-year-old man presented with fevers and abdominal pain then rapidly deteriorated into cardiogenic shock. His constellation of symptoms along with elevated inflammatory markers in the setting of a recent SARS-CoV-2 infection was consistent with the diagnosis of MIS-A. He also had a comprehensive infectious workup that was unremarkable, ruling out other potential infectious aetiologies for his presentation. He subsequently improved through supportive measures and after administration of intravenous immunoglobulin (IVIG). He later demonstrated recovery of cardiac function and cardiac magnetic resonance imaging (MRI) showed signs consistent with myocarditis. Discussion: As the COVID-19 pandemic continues to be an ongoing issue, it is important to recognize MIS-A, a rare and potentially deadly clinical syndrome that can lead to profound cardiovascular complications. Non-invasive imaging modalities such as cardiac MRI can play a role in the identification of myocarditis. In addition to supportive management, adjunctive therapies such as IVIG may be efficacious in MIS-A and should be further investigated.